HSBC downgraded Novo Nordisk (NVO) to Hold from Buy with a $57 price target The firm says its thesis that Novo would regain obesity market share due to the FDA’s ban on compounding has not played out. The U.S. compounders continue to sell these drugs illegally and there are limited reasons for the situation to change in the near-term, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Is Novo Nordisk Stock a Falling Knife? Here’s What This Top Investor Thinks
- Novo Nordisk price target lowered to DKK 500 from DKK 650 at JPMorgan
- Eli Lilly Stock (LLY) Will Benefit from ‘Onshoring Boom,’ Says BMO Capital Markets
- Notable open interest changes for July 30th
- Novo Nordisk downgraded to Neutral from Buy at BofA